beware the tree shakers, before the rise, page-12

Westhx,

The overall market has been down over the last few days. The uncertainty may have forced a few early exits from PRR.

It is interesting that the news of the appointment of the COO in Europe seems to have had little effect on the share price.

As reiterated by several posters, the management team is sound, the results so far have been promising and there is additional know-how support from DNDN. Plus, the quarterly statement (pages 5 and 6) shows that they have approx $13 million cash (at the end of Dec 09) and they used up approx $1.4 million in that quarter (operating Cash Flow). So they seem to be fine in terms of cash as well.

The market seems to be waiting for the ODS and/or the phase IIb trials going past the patient recruitment phase.

The uncertainty is high and the market is probably showing that through the price. Hopefully one (or both) of the two big-ticket items of ODS and physical start to the phase IIb trials happen soon.

Cheers,

Jai.